At NovoHelix, we take on biomedical challenges with competition and rigor, and we are not afraid to take risks to achieve our goals. NovoHelix has demonstrated research acumen for the development of novel technologies for complex genome engineering of mammalian embryos and cells. Our model design team is experienced with multiple DNA-writing and DNA-editing technologies including CRISPR-Cas systems, TALENs, zinc finger nucleases (ZFN), meganucleases, gene targeting by homologous recombination and phage recombineering. We have a reputation for advancing biomedical model generation in both rodents and livestock, creating customized disease-in-a-dish human pluripotent cell lines, and advancing microbial chromosome engineering for custom industrial strain needs. Please describe your project goals using our online Request Form and a member of our team will respond within 2 business days.